Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.62 |
| ▸ | CA2 | P00918 | 6/20 | 0.62 |
| ▸ | CA4 | P22748 | 6/20 | 0.62 |
| ▸ | CA6 | P23280 | 4/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110014 | 1.00 | CA1 (0.62) | CA1CA2CA4CA6SLC18A3 | |
| SCHEMBL16995166 | 0.97 | — | — | |
| SCHEMBL43179 | 0.97 | — | — | |
| SCHEMBL13973916 | 0.97 | — | — | |
| SCHEMBL11967081 | 0.97 | — | — | |
| SCHEMBL3038801 | 0.97 | — | — | |
| SCHEMBL12127053 | 0.97 | — | — | |
| SCHEMBL14161812 | 0.97 | — | — | |
| SCHEMBL3038803 | 0.97 | — | — | |
| SCHEMBL2288017 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1710223-B1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-7332632-B2 | Method for producing aldehyde compound or ketone compound by using microreactor | Ubē Industries, Ltd. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | UBE INDUSTRIES, LTD., A CORPORATION OF JAPAN (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1710223-A1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | Ube Industries, Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-0902786-B1 | SYNTHESIS OF CYCLOALKYLDIARYLPHOSPHINES | ALBEMARLE CORP (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-0902786-A1 | SYNTHESIS OF CYCLOALKYLDIARYLPHOSPHINES | ALBEMARLE CORPORATION (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5710340-A | Synthesis of cycloalkyldiarylphosophines | ALBEMARLE CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997041131-A1 | SYNTHESIS OF CYCLOALKYLDIARYLPHOSPHINES | ALBEMARLE CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | CA1 2748/4885CA2 555/4885CA4 2304/4885 |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | ADH1C, ADH1A, ALDH1A1 | CA1 1026/4885CA2 2767/4885CA4 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.